LBEL LEDERM 35plus Jour

Product NDC: 13537-445
11-digit product format: 135370445
Labeler code: 13537
Product ID: 13537-445_a2d166f7-69ae-42e5-9f3c-46c34ec0f739
Type: HUMAN OTC DRUG
Nonproprietary name: Avobenzone, Octisalate, Octocrylene, and Oxybenzone
Dosage form: CREAM
Route: TOPICAL
Labeler: Ventura Corporation LTD.
Application: part352
Marketing category: OTC MONOGRAPH FINAL
Marketing start: 2013-04-01
Marketing end: 0000-00-00
Substance: AVOBENZONE; OCTISALATE; OCTOCRYLENE; OXYBENZONE
Active strength: 0 g/g; g/g; g/g; g/g
NDC exclude flag: E
Listing certified through: 2018-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 4 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Source date
excluded product	product	13537-445		D	Discontinued by firm	2026-10-05
excluded package	package	13537-445	13537-445-01	D	Discontinued by firm	2026-10-05
excluded package	package	13537-445	13537-445-04	D	Discontinued by firm	2026-10-05
excluded package	package	13537-445	13537-445-06	D	Discontinued by firm	2026-10-05

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 2 · 88 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Dataset, Scope table
Captured / source date	Dataset	Scope	Package NDC	Code	Status	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	excluded product	product		D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	13537-445-04	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	13537-445-01	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-12-14 17:58 UTC · source 2025-12-05	excluded package	package	13537-445-06	D	Discontinued by firm	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded product	product		D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	13537-445-04	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	13537-445-01	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-08-27 00:01 UTC · source 2025-08-26	excluded package	package	13537-445-06	D	Discontinued by firm	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded product	product		I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	13537-445-01	I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	13537-445-04	I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-04-01 02:39 UTC · source 2025-03-31	excluded package	package	13537-445-06	I	Inactivated by FDA	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded product	product		I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	13537-445-01	I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	13537-445-04	I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-28 20:22 UTC · source 2025-03-28	excluded package	package	13537-445-06	I	Inactivated by FDA	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded product	product		I	Inactivated by FDA	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	13537-445-01	I	Inactivated by FDA	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	13537-445-04	I	Inactivated by FDA	`cfe11265f3b6…`	`090c488252e2…`
2025-03-22 03:12 UTC · source 2025-03-21	excluded package	package	13537-445-06	I	Inactivated by FDA	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded product	product		I	Inactivated by FDA	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	13537-445-01	I	Inactivated by FDA	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	13537-445-04	I	Inactivated by FDA	`cdf11ea48f46…`	`ba0047e9e063…`
2025-03-10 12:48 UTC · source 2025-03-10	excluded package	package	13537-445-06	I	Inactivated by FDA	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded product	product		I	Inactivated by FDA	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	13537-445-01	I	Inactivated by FDA	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	13537-445-04	I	Inactivated by FDA	`302b2466d912…`	`e7b80fea0513…`
2025-02-02 03:52 UTC · source 2025-01-31	excluded package	package	13537-445-06	I	Inactivated by FDA	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded product	product		I	Inactivated by FDA	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	13537-445-01	I	Inactivated by FDA	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	13537-445-04	I	Inactivated by FDA	`ed331223b511…`	`672a5bd82f5f…`
2025-01-20 13:05 UTC · source 2025-01-20	excluded package	package	13537-445-06	I	Inactivated by FDA	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded product	product		I	Inactivated by FDA	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	13537-445-01	I	Inactivated by FDA	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	13537-445-04	I	Inactivated by FDA	`0efc9e666f02…`	`f202fb6c5f17…`
2025-01-11 03:41 UTC · source 2025-01-10	excluded package	package	13537-445-06	I	Inactivated by FDA	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded product	product		I	Inactivated by FDA	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	13537-445-01	I	Inactivated by FDA	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	13537-445-04	I	Inactivated by FDA	`ad56d346431e…`	`cc804d4bbf1e…`
2024-11-09 02:27 UTC · source 2024-11-08	excluded package	package	13537-445-06	I	Inactivated by FDA	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded product	product		I	Inactivated by FDA	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	13537-445-01	I	Inactivated by FDA	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	13537-445-04	I	Inactivated by FDA	`367a005e9d99…`	`383a685ebd0f…`
2024-10-04 04:10 UTC · source 2024-10-03	excluded package	package	13537-445-06	I	Inactivated by FDA	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded product	product		I	Inactivated by FDA	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	13537-445-01	I	Inactivated by FDA	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	13537-445-04	I	Inactivated by FDA	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-07-10 04:00 UTC · source 2024-07-09	excluded package	package	13537-445-06	I	Inactivated by FDA	`557ba5c1ecfa…`	`9c80585c8c6e…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded product	product		I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	13537-445-01	I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	13537-445-04	I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-28 21:12 UTC · source 2024-05-28	excluded package	package	13537-445-06	I	Inactivated by FDA	`8af77b9d5b6f…`	`d9bbb34c5368…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded product	product		I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	13537-445-01	I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	13537-445-04	I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-05-15 03:39 UTC · source 2024-05-14	excluded package	package	13537-445-06	I	Inactivated by FDA	`834df4deac94…`	`adcc014656a3…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded product	product		I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	13537-445-01	I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	13537-445-04	I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`
2024-03-11 06:39 UTC · source 2024-03-08	excluded package	package	13537-445-06	I	Inactivated by FDA	`1332a3947898…`	`d4bfe170f9cd…`

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Related label table
NDC	Effective	Related label
13537-445-01	2025-04-24	L'BEL LEDERM 35plus Jour SPF 15 Facial Treatment Against First Signs of Aging Day - Normal to Dry Skin
13537-445-04	2025-04-24	L'BEL LEDERM 35plus Jour SPF 15 Facial Treatment Against First Signs of Aging Day - Normal to Dry Skin
13537-445-06	2025-04-24	L'BEL LEDERM 35plus Jour SPF 15 Facial Treatment Against First Signs of Aging Day - Normal to Dry Skin
13537-445-01	2020-01-31	L'BEL LEDERM 35plus Jour SPF 15 Facial Treatment Against First Signs of Aging Day - Normal to Dry Skin
13537-445-04	2020-01-31	L'BEL LEDERM 35plus Jour SPF 15 Facial Treatment Against First Signs of Aging Day - Normal to Dry Skin
13537-445-06	2020-01-31	L'BEL LEDERM 35plus Jour SPF 15 Facial Treatment Against First Signs of Aging Day - Normal to Dry Skin

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
Avobenzone	ACTIVE INGREDIENT	G63QQF2NOX	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
Octisalate	ACTIVE INGREDIENT	4X49Y0596W	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
Octocrylene	ACTIVE INGREDIENT	5A68WGF6WM	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
Oxybenzone	ACTIVE INGREDIENT	95OOS7VE0Y	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
Avobenzone	ACTIVE MOIETY	G63QQF2NOX	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
Octisalate	ACTIVE MOIETY	4X49Y0596W	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
Octocrylene	ACTIVE MOIETY	5A68WGF6WM	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
Oxybenzone	ACTIVE MOIETY	95OOS7VE0Y	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
.ALPHA.-TOCOPHEROL ACETATE	INACTIVE INGREDIENT	9E8X80D2L0	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
ACACIA	INACTIVE INGREDIENT	5C5403N26O	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
ALKYL (C12-15) BENZOATE	INACTIVE INGREDIENT	A9EJ3J61HQ	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
BUTYLENE GLYCOL	INACTIVE INGREDIENT	3XUS85K0RA	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
CAROB	INACTIVE INGREDIENT	5MG5Z946UO	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
CHLORPHENESIN	INACTIVE INGREDIENT	I670DAL4SZ	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
CYCLOMETHICONE 6	INACTIVE INGREDIENT	XHK3U310BA	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
DIMETHICONE	INACTIVE INGREDIENT	92RU3N3Y1O	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
EDETATE DISODIUM	INACTIVE INGREDIENT	7FLD91C86K	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
GLYCERIN	INACTIVE INGREDIENT	PDC6A3C0OX	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
GLYCERYL MONOSTEARATE	INACTIVE INGREDIENT	230OU9XXE4	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
HYDROGENATED PALM GLYCERIDES	INACTIVE INGREDIENT	YCZ8EM144Q	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
NIACINAMIDE	INACTIVE INGREDIENT	25X51I8RD4	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
PEG-100 STEARATE	INACTIVE INGREDIENT	YD01N1999R	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
PENTYLENE GLYCOL	INACTIVE INGREDIENT	50C1307PZG	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
PHENOXYETHANOL	INACTIVE INGREDIENT	HIE492ZZ3T	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
POTASSIUM CETYL PHOSPHATE	INACTIVE INGREDIENT	03KCY6P7UT	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
PRUNUS PERSICA LEAF	INACTIVE INGREDIENT	VN3501T41P	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
SILICON DIOXIDE	INACTIVE INGREDIENT	ETJ7Z6XBU4	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
SODIUM HYDROXIDE	INACTIVE INGREDIENT	55X04QC32I	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
WATER	INACTIVE INGREDIENT	059QF0KO0R	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
XANTHAN GUM	INACTIVE INGREDIENT	TTV12P4NEE	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1
YEAST	INACTIVE INGREDIENT	3NY3SM6B8U	LBEL LEDERM 35PLUS JOUR SPF 15 FACIAL TREATMENT AGAINST FIRST SIGNS OF AGING DAY - NORMAL TO DRY SKIN (AVOBENZONE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE) CREAM [VENTURA CORPORATION LTD.]	1

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
G63QQF2NOX	AVOBENZONE	70356-09-1	AVOBENZONE
4X49Y0596W	OCTISALATE	118-60-5	OCTISALATE
5A68WGF6WM	OCTOCRYLENE	6197-30-4	OCTOCRYLENE
95OOS7VE0Y	OXYBENZONE	131-57-7	OXYBENZONE

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
Avobenzone, Octisalate, Octocrylene, and Oxybenzone	Ventura Corporation LTD. \| Bel Star S.A. (Colombia) \| Yobel Supply Chain Management S.A. (Peru)	2013-04-01	HUMAN OTC DRUG LABEL	1

LBEL LEDERM 35plus Jour

NDC auxiliary status#

Observed NDC auxiliary status history#

Reported adverse events (FAERS/openFDA)#

FDA-Initiated Inactive NDC Indexing#

DailyMed Socrata Ingredients#

Related Records#

Related UNII Ingredients#

Related DailyMed Labels#